Physician profile

Joy Ann Hart

Obstetrics & Gynecology · Sidney, OH

NPI 1285081042

$228.05

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$63.24

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $55.79 2021-2022
Therapeuticsmd, INC. $34.08 2022
Gynesonics, INC. $28.69 2023 Sonata Sonography-Guided Transcervical Fibroid Ablation System
Minerva Surgical, INC $22.98 2021
Bayer Healthcare Pharmaceuticals INC. $20.50 2023
Hologic Sales and Service, LLC $17.61 2022
Medtronic, INC. $17.23 2022
Davol INC. $17.12 2019
Organon LLC $14.05 2023 Nexplanon

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Joy Ann Hart

$228.05

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/2540437/joy-ann-hart

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.